Our Mission
Kinevant Sciences (kine-a-vant) is developing new therapies for rare inflammatory and autoimmune diseases.
Our Science
Kinevant’s lead investigational product candidate, namilumab*, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor (GM-CSF), a key pro-inflammatory cytokine involved in inflammatory disorders.
*Namilumab is not approved in any market.
